A MESSAGE FROM THE PRESIDENT

Looking back at 2019 and assessing the National Breast Cancer Coalition’s (NBCC’s) work allowed me a moment of respite from an all-consuming pandemic. Not that dealing with the impact of a lethal disease is at all comforting. But breast cancer patients and survivors live with uncertainty every day. What is the best treatment for me? Do I have to worry about a recurrence? Will my daughter or mother be diagnosed? Will my insurance cover any costs? What can I do? Is there hope for a solution in my lifetime?

For NBCC advocates, it’s the challenge of finding answers and solutions to the uncertainty that drives us. It requires us to look at what we know, what we can change, and how to impose boundaries around the uncertainty. How to break through those boundaries. And that is what NBCC does — whether it’s through the ARTEMIS Project® where we’re searching for a vaccine to prevent breast cancer or figuring out how to stop metastasis, or through Project LEAD® where advocates learn to participate at all levels of breast cancer decision making. We bring together many voices and perspectives into one meaningful agenda and take it to Capitol Hill and the White House. By empowering ourselves, boldly advocating, and challenging the status quo, NBCC is forcing change.

So, while no one knows the extent to which this pandemic will change our world, one thing is certain — NBCC’s dedication and commitment to saving lives and ending breast cancer is steadfast. That will never change.

Thank you for being part of our mission to end breast cancer — for all of us and for future generations.

Frances M. Visco
President, National Breast Cancer Coalition
NBCC’s ARTEMIS Project®, an advocate-led research collaboration, brings together various stakeholders in an innovative, mission-driven approach that includes strategic summits, catalytic workshops, and research action plans. Artemis has two areas of focus: Primary Prevention — how to stop women and men from getting breast cancer — and Prevention of Metastasis — how to stop breast cancer from becoming lethal.

Each year, we host a meeting of Artemis participants to report on accomplishments and develop plans for the next 12-18 months. Throughout the year, participants move action plans forward and engage in webinars and conference calls to refine plans and provide additional input.

Prevention of Metastasis
At the 2019 meeting, a subgroup looked specifically at the technology needed to help answer tumor dormancy issues. They addressed questions, such as whether any existing technology could provide a real-time view of what happens during the metastasis process? Also, if that technology doesn’t exist yet, could it be developed? The outcome led to the development of a plan to leverage innovative technology to “see” the process of metastasis and how to intervene.

Primary Prevention
Vaccine
Plans to finalize the Investigational New Drug application (IND) and the Phase 2 clinical trial were discussed, and a Vaccine Project Manager was contracted to work with the vaccine team to advance the Phase I trial.

Other Prevention Approaches
ARTEMIS participants continue to discuss other research topics in the area of primary prevention, such as exploring aspects of the microbiome and risk stratification.
Clinical Trials
In 2019, NBCC began its collaboration with Translational Research In Oncology (TRIO) and Novartis on a clinical trial of CDK4/6 inhibitors in early high-risk HR+/HER2- breast cancer, the NATALEE trial. NBCC advocates have been working closely with TRIO as an advocate partner to support this trial. Our advocates serve on the clinical trial steering committee, the data safety monitoring board, and the translational research committee.

DNA.Land
In 2017, the DNA.Land project was launched asking individuals to submit results of genetic tests done through various companies that perform genome testing on saliva and answer a clinical questionnaire specific to breast cancer. The goal is to develop a database resource to help determine why some breast cancers recur. Over 30,000 people completed the clinical questionnaire. In 2019, the databases were delivered to NBCC and we are convening an advisory group to guide the development of policies and procedures for data sharing and management.
EDUCATION AND TRAINING

Team Leader Training
In March 2019, NBCC brought selected breast cancer advocates from around the country to Washington, DC for intensive training and development in grassroots advocacy, the federal legislative process, the NBCC legislative and public policy agenda, and lobbying techniques. Following training and preparation, activists spread across Capitol Hill meeting with Senators and Representatives or their staff members to discuss and forward NBCC’s legislative and public policy agenda. NBCC’s trained Team Leaders also led state delegation visits on Capitol Hill during our annual membership lobby day. Additionally, NBCC Field staff hosted monthly leadership strategy conference calls.

Advocate Leadership Summit
An energized, committed, and passionate group of more than 130 NBCC leaders attended our 2019 Advocate Leadership Summit in Arlington, VA in late April. The Summit was praised as “the best ever” by participants. Thought-provoking plenary sessions followed on topics, such as “Conflicts of Interest and Their Impact on Breast Cancer Research,” “The Science of Advocacy,” as well as updates on the progress of the ARTEMIS Project, and conversations about navigating health care policy in the political environment. There were also eight
skill-building workshops on varied topics, such as disparities in breast cancer, informed consent in clinical research, clinical trial design, and the value of transparency in cancer drug development.

**Breast Cancer Caucus**

NBCC developed the Breast Cancer Caucus, a public policy organizing and advocacy effort around presidential elections. Each presidential election cycle, NBCC conducts a campaign to educate the candidates about the meaningful public policy approaches necessary to end breast cancer and to give them an opportunity to show their support for our mission. We inform the public about where the candidates stand on NBCC’s agenda.

In 2019, all of the Democratic candidates and one Republican candidate, endorsed the NBCC policy platform that details the actions they will take on related public policy priorities. NBCC activists intend to hold candidates to their promises, and we are once again ready to push for the initiatives needed to achieve our mission to end breast cancer.
Project LEAD®
NBCC hosted another successful Project LEAD Institute in La Jolla, California in July, 2019. With a diverse class of 58 advocates, 2019 had one of the largest classes ever — a 38% increase over 2018. Attendees gathered for a week of intense, dedicated study. The 2019 class included participants from 21 different states, the District of Columbia, Puerto Rico, Canada, and Australia.

Throughout the year, NBCC offered Project LEAD graduates continuing education through online webcasts, conference calls, training webinars, regular updates, and an annual meeting at NBCC’s Advocate Leadership Summit.

Project LEAD Grant
In 2019, NBCC received a two-year Eugene Washington Engagement Award from the Patient-Centered Outcomes Research Institute (PCORI) to expand the capacity of Project LEAD’s virtual training for advocates around clinical trial methodology, comparative effectiveness research (CER), and PCOR.

Webinars
As part of its education and training programs, NBCC conducted several webinars in 2019, on topics, such as “Clinical Trials — Designs, Methodology, and Key Issues for Research Advocates” “Vaccines for Breast Cancer — Where Are We in 2019?” and “Dissecting the Tissue Specificity of Cancer Drivers.”
The National Breast Cancer Coalition Board of Directors establishes NBCC’s legislative and public policy priorities. Each year, issues are brought to the attention of NBCC staff, who conduct research and prepare background information for the Board to review. At the January Board meeting, the members voted on the top legislative priorities. NBCC made significant progress on the 2019 priorities.

**DoD Breast Cancer Research Program**
In 1992, the Department of Defense Breast Cancer Research Program (DOD BCRP) started as a result of NBCC’s campaign to increase federal appropriations for breast cancer research. The program remains a top priority for NBCC. Thanks to the hard work of NBCC advocates, Congress appropriated $150 million for FY 2020, an increase from $130 million in FY 2019.

**Metastatic Breast Cancer Access to Care Act**
NBCC’s priority legislation (S. 1374/H.R. 2178) The Metastatic Breast Cancer Access to Care Act was reintroduced, and our advocates were responsible for obtaining strong bi-partisan support. By the end of 2019, NBCC had secured 131 cosponsors in the House and 13 in the Senate.

**Annual Membership Lobby Day**
During our annual membership lobby day in April, NBCC advocates held more than 300 meetings with their members of Congress on Capitol Hill. Back in home districts, advocates attended town halls, and published letters to the editor in their local papers to advocate for NBCC’s priorities.
2019 EVENTS

NBCC’s 19th Annual Les Girls
Les Girls Cabaret was held in October at the Avalon Theater in Hollywood. The evening featured an all-star lineup of performers, capped by an unforgettable performance by Carole King.

NBCC’s 24th New York Gala
Our New York Gala honored two breast cancer advocates, Dale Eastman and Valencia Robinson, as well as Devika Bulchandani, president, McCann New York, for their ongoing work to help NBCC. Joey McIntyre provided the entertainment, performing several songs for the crowd.
And More...

The third annual **Women with Balls®** NYC and the 14th annual Washington, DC events brought together like-minded, compassionate, and energetic supporters to bowl and raise money for a great cause.

Hauser & Wirth hosted an **evening of art** to benefit NBCC. The evening featured a private view of the Philip Guston exhibition, and a presentation by the artist’s daughter, Musa Mayer. NBCC was the beneficiary of the West Coast’s largest pro **women’s squash doubles event**. Held at the prestigious Jonathan Club, the event was a competitive draw featuring world class athletes and a Pro-Am draw.
OUTREACH

NBCC either presented at or attended a number of national meetings on the issue of clinical trials research, patient advocate involvement in clinical trials, and Deadline 2020 research efforts. These included the National Cancer Institute, the Integration Panel of the Department of Defense Breast Cancer Research Program, and the San Antonio Breast Cancer Symposium.

NBCC, Fran Visco, and advocates continued to comment on breast cancer news and health care policy with statements appearing in news outlets such as *USA Today*, *StatNews*, *Scienceblog*, and *HealthNewsReview*.
YOUR DOLLARS AT WORK

2019 Expenses $3,574,356*

- **FUNDRAISING** 9.5%
- **EDUCATION & TRAINING** 30%
- **CATALYTIC RESEARCH** 20%
- **MANAGEMENT & GENERAL** 6%
- **OTHER PROGRAMS** 3.5%
- **PUBLIC INFORMATION** 9.5%
- **PUBLIC POLICY** 15%
- **GRASSROOTS, ETC** 6.5%

**Note:** Pie-chart reflects expenses of $3,136,593 — It does not include event related direct benefits to donors $437,763.

### Assets 2019

<table>
<thead>
<tr>
<th>Asset</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; Cash Equivalents</td>
<td>$1,222,922</td>
</tr>
<tr>
<td>Accounts Receivables</td>
<td>$559,327</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>$157,025</td>
</tr>
<tr>
<td>Net Property &amp; Equipment</td>
<td>$175,768</td>
</tr>
<tr>
<td>Deposits</td>
<td>$57,134</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$2,223,139</td>
</tr>
<tr>
<td><strong>LIABILITIES</strong></td>
<td>$307,146</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td>$1,915,993</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES &amp; ASSETS</strong></td>
<td>$2,223,139</td>
</tr>
</tbody>
</table>

### 2019 Public Support & Other Revenue $3,858,200*

- **2%** Other revenue $66,003
- **7%** Corporation & Foundations $283,425
- **48%** Restricted Grants $1,866,287
- **28%** Special Events $1,086,490
- **15%** Individuals $555,995

*Total Expense and Total Revenue include event costs that are direct benefits to donors, $437,763.
2019 BOARD OF DIRECTORS

ABCD: After Breast Cancer Diagnosis
Bonnie Anderson (D)
Ginny Finn (A)

Alamo Breast Cancer Foundation
Jerry Worden (D)
Beth Emery (A)

American Association of Breast Care Professionals
Rhonda Turner (D)
Gretchen Walton (A)

Annie Appleseed Project
Ann Fonfa (D)
Rasheedah Ahmad (A)

Breast Cancer Care and Research Fund
Michele Rakoff (D)
Michele Atlan (A)

CARE Advocates Network
Carol Matyka (D)
Karen Poliseno (A)

Cedar Valley Cancer Committee: Beyond Pink TEAM
Christine Carpenter (D)
Lori Seawel (A)

Cedars Sinai Breast Center
Sherry Goldman (D)
Sylvia Estrada (A)

Delaware Breast Cancer Coalition, Inc.
Francesca Vogel (D)
Susan Murray (A)

Dr. Susan Love Research Foundation
Judi Hirshfield-Bartek (D)
Christopher Clinton Conway (A)

Georgia Breast Cancer Coalition Fund
Sheryl Cherico (D)

Linda Creed Breast Cancer Foundation
Donna Duncan (D)
Linda Camerota (A)

Louisiana Coalition of African American Breast Cancer Survivors
Julia Bradford Moore (D)
Eunice Lavigne (A)

Metropolitan Washington, DC Chapter of NBCC
Wanda Lucas (D)

Michigan Breast Cancer Coalition
Rose Marie Sitko (D)
Jeanne Deneweth (A)

Minnesota Breast Cancer Coalition
Christine Norton (D)
Pat Haugen (A)

National Breast Cancer Coalition
Frances M. Visco (D)

Nueva Vida
Astrid Jiménez, Esq. (D)
Gloria Elliott (A)

SHARE
Ivis Febus-Sampayo (D)
Helen Schiff (A)

St. Louis Breast Cancer Coalition
Mary Lynn Faunda Donovan (D)
Sheila McGlown (A)

Virginia Breast Cancer Foundation
Susan Siegel (D)
Katy Sawyer (A)

Young Survival Coalition
Joy Simha (D)

(D) — Director
(A) — Alternate
National Breast Cancer Coalition Fund

2019 BOARD OF TRUSTEES

Alec R. Call
Sherry Goldman RN, NP, MSN
Ira Hillman, Treasurer
Judi Hirshfield-Bartek, RN, MS, OCN
Bryan Johns
Liane Martins Lindner, Chair
Nicole Maloney
Sharon Nelles, JD
Christine Norton, MA, Secretary
Michele Rakoff
Linda Rothweiler, DMD, Vice Chair
Dennis Slamon, MD, PhD
Frances M. Visco, JD, President
Carol Vance Wall
2019 DONORS

$250,000 & Above
Celgene
Dorian S. Goldman and Marvin Israelow
Joyce and Irving Goldman Family Foundation
Katja Goldman and Michael Sonnenfeldt
Lloyd and Victoria Goldman
Carol and Terry Wall
Vance Wall Foundation

$100,000-$249,000
Alec Call and Bryan Johns
Cindy and Alan Horn
The Horn Foundation
iS CLINICAL by INNOVATIVE SKINCARE
Musa and Tom Mayer
National Philanthropic Trust
Translational Research in Oncology-US, Inc. (TRIO-US)

$50,000-$99,999
Anonymous
Judges and Lawyers Breast Cancer Alert
Patient-Centered Outcomes Research Institute

$25,000-$49,999
The Allergan Foundation
Genomic Health, Inc.
Robert & Shirley Harris Family Foundation
William Laggren + Longchamp USA, Inc.
Nicole Maloney
The Maloney Family Foundation
Novartis Oncology
Pfizer Inc.
Steve Tisch Family Foundation

$10,000-$24,999
The Barth Family Foundation
CARE Advocates
Cody Horn Carolin and Reid Carolin
Stephen P. and Sarah Chapin Columbia
Kathleen Dwyer
Kevin Feige
Cassidy Horn
JPMorgan Chase
The Marilyn and Jeffrey Katzenberg Foundation
Judy and Peter Kovler
Judy and Peter Blum Kovler Foundation
McCann New York
Mellam Family Foundation

$5,000-$9,999
Anonymous
Kathy M. Ball
Gerry Bernardi and Joe Keenan
Breakform Residential Fund
Debbie and James Burrows
Nancy and Dwayne Burton
Capital Group
Eisenberg, Rothweiler, Winkler, Eisenberg & Jeck, P.C.

Peter Morton
New Regency Productions, Inc.
Nancy Pelosi
John Perenchio
Michele Rakoff and Alan Sieroty
The Rosenthal Family Foundation
Dr. Linda and Ken Rothweiler
Arleen F. Sorkin and Christopher Lloyd
Sullivan & Cromwell LLP
Fern and Lenard Tessler
Turner Foundation Inc.
Fran M. Visco and Arthur N. Brandolph
Women’s Squash Doubles Association
Ann C. Yahner

+ Deceased
Beth Emery
Patricia L. Freysinger
David Geffen
Foundation
Goldman-Sonnenfeldt
Foundation
Courtney S. Hollander
Interpublic Group
The Hall Charitable
Trust
Lonnie L. Israel
Susan K. Johns
Blake T. Johns and
Brittany Shaw
Gail Kamer
Suzanne and Ric Kayne
Lyn and Norman Lear
Barbara Silver Levin
Foundation
Liane M. Lindner
Susan F. and James E.
Lindsay
Joseph Meltzer
Merck & Co., Inc.
Ron M. Meyer
Jonathan Moss
Christine K. and
Dermot Norton
John Noss
Karl Ravancho
Everett D. Reese II
Fred Rosen
Safra National Bank
of New York
Helen Schiff and
Richard Congress
The StudBuddy LLC
Pamela West
Ziffren Brittenham LLP

$2,500-$4,999
Geoff Adamson
Susanna Lachs Adler
and Dean Adler
Debbie and Mark
Attanasio
Violaine and John
Bernbach
Beverly Birnbaum
Christine B. and
Delburn Carpenter
Ashley Catronio
Cedar Valley Cancer
Committee: Beyond
Pink TEAM
Christopher C. Conway
Dr. Judy Dering and Dr.
Frank Calzone
Ulysses De Santi
Donna Duncan
Eversheds Sutherland
Genesis10
Dr. Armando Giuliano
Sherry and Barry
Goldman

Pennelope Goodfriend
Kathleen and Arthur
Harris
Ira Hillman and Jeremy
Barber
Barry Hirsch
Judi J. Hirshfield-Bartek
and Elmer Bartek
Lisa Jacobson
Minnesota Breast
Cancer Coalition
Terri New
Bill Nye
James D. Parriott and
Diane Cary
Paul Hastings LLP
Carol and Michael
Pliner
Pamela Romanow
Nancy A. and James
Ryan
Saul Ewing, LLP
The Streisand
Foundation
Throw Pink
Katherine K. Tobin
Robin Wayne

We have done our best to review these lists. If anything appears incorrect, please accept our apologies and contact NBCC’s Development Office at 202-973-0573 or info@stopbreastcancer.org.
The President's Council recognizes donors who gave unrestricted funds of $1,000 or more in any of the last three years to support our mission to end breast cancer. These donors receive special benefits, such as communications on current breast cancer issues and invitations to special events. To join or for questions, call the Development team at 202-973-0573.

Edite Abolins
Madeline and Stephen Anbinder
Carla and Michael Angelo
Susan and Robert Appleton
Kathy M. Ball
Annette and Avram Bar-Cohen
Carol A. Beagan
Lori and Bob Beck
Violaine and John Bernbach
Laurel Bezanson
Dr. David Biro and Daniella Vitale
Dr. Isabelle T. Bisceglio
Carmella Bocchino
Steve B. Bonner
Daniel Bonoff
Donna Brogan
Bruce Brown
Janet F. and George R. Buckley
Christine Burns
Alec Call and Bryan Johns

+ Deceased

Maureen Calloway Carnevale and Richard Carnevale
Christine B. and Delburn Carpenter
Richard Cassese
Ashley Catronio
Carol and Richard Chadakoff
Jan R. Cloyde
Victoria G. Cooke
Emily and John M. Costigan
Elaine M. Coughlin
Dr. Judith C. & David Craver
Susan M. Dacks
Doreen and Robert Davis
Dr. Judy Dering and Dr. Frank Calzone
Karen Di Nunzio
Dr. Kay Dickersin and Robert Van Wesep
Betty J. Dietrich
Donna Duncan
Kate Dwyer
Dale and Harry Eastman
Dr. Stephen J. Elledge
Dr. Matthew and Rosana Ellis
Beth Emery
Ileane and Irvin Fagin
Lynne Farrow
Kevin Feige
Phyllis Fern
Alan B. Fleischer
Dr. Silvia C. Formenti
Elizabeth and Richard Frank
Meryl French
Patricia L. Freysinger
Jeffrey C. Golden
Dorian S. Goldman and Marvin Israelow
Katja Goldman and Michael Sonnenfeldt
Lloyd and Victoria Goldman
Sherry and Barry Goldman
Stephanie and Josh Goldstine
Nancy Goler
Pennelope Goodfriend
George T. Grant
Amy Gross
Kathleen and Arthur Harris
Pat Haugen
Robert E. Haydon
Gail Haynes
Susan R. Hester
Ira Hillman and Jeremy Barber
Judi J. Hirshfield-Bartek and Elmer Bartek
Cathy S. Holloway
Joanne M. Howes
Rosemary and Alfred W. Iversen
Lisa Jacobson
Harris Jaffe
Linda A. Jbara
Natalie R. Kase
Neil Katcher
John A. Kay
Diana Wendy and Hugh Kendrick
Janet C. Kossman
Judy Kovler
Summer Krywucki
William Laggren +
Dr. Leona Laskin
Tracy E. Leduc
Paula Levine and Dr. Bernard Beitman
Karen and Franklin Lewkowitz
Susan F. and James Lindsay
Dr. Nancy Lisagor
Caroline and James Losty
Hannah Low
Wanda A. Lucas
Lawrence B. Ludwig
Dr. Ngina Lythcott and Byllye Avery
Nicole Maloney
Carol Matyka
Mary Matyka
Michele May and Dr. David R. Walt
Musa and Tom Mayer
Dorrie McCaffrey
Joseph P. McCarthy
Carolyn C. McCormick
Jacqueline McMullen
Catherine M. Meek and Al Earle
Beth Sieroty Meltzer
Joseph Meltzer
Rose Mennella
Randall J. Miles
Christine M. Millen
Stephen and Viv Moeller
Gayle A. Nobbs
Melinda S. and Scott Nordeng
Christine K. and Dermod Norton
John Noss
Norma and Dr. Norman + Nutman
Bill Nye
Jeanne Olson
Leigh Pate
Michele Rakoff and Alan Sieroty
Pamela Romanow
Marilyn Rosskam
Rosemary Rosso, JD
Dr. Linda and Ken Rothweiler
Nancy A. and James Ryan
Helen Schiff and Richard Congress
Marilyn Schiffer
Gail and Dr. Steven Shak
Lauren Shuler Donner
Joy A. Simha and Vasu Chari
Carly Simon
Janet E. Simon
Arleen F. Sorkin and Christopher Lloyd
Sharon Sutter
Nicki and Harold Tanner
Doreen Taras
Anna Tello
Toby Thomas
Jeffrey and Dina Tranen
John VerSteeg
Fran M. Visco and Arthur N. Brandolph
Madeline and Dr. Richard Wachter
Elizabeth Wade
Carol and Terry Wall
Jerry L. Worden
Ann C. Yahner
Dr. Stanley E. Zeitz
The National Breast Cancer Coalition Fund is a 501 (c)(3) entity that designs and runs programs to educate, train, and inform advocates, policymakers, scientists, providers, and the public about breast cancer science, health care and advocacy. The Fund collaborates with the research community on innovative research, effects change in the health care system to advance access to quality health care for all, and gives a powerful, effective voice to breast cancer advocates everywhere.

The National Breast Cancer Coalition is a 501 (c)(4) organization that designs and works to enact legislation, policy, and regulation to end breast cancer. The Coalition lobbies through its grassroots network for increased funding for innovative research, a seat at the table to oversee how those funds are spent, and public policies to expand access to quality health care for all.